SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT ON FORM 8-K
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: June 3, 1997
(Date of Earliest event reported)
*******************************
MEDIZONE INTERNATIONAL, INC.
----------------------------
(Exact name of Registrant as specified in its charter)
Nevada 2-93277-D 87-0412648
State of Commission IRS Taxpayer
Incorporation Registration No. I.D. Number
21 Cummings Park, Suite 274, Woburn, Massachusetts 01801
--------------------------------------------------------
Address of Principal executive offices
Registrant's telephone number: (617) 908-6366
--------------
<PAGE>
Item 5. Other Events
------------
Medizone International, Inc. (the "Registrant") announced today that during
its investigation into the conduct of the Registrant's operations during the
tenure of Joseph S. Latino, Ph.D. as the Registrant's Chairman, President and
Director of Research, it learned that human trials of the Registrant's ozone
therapy on patients infected with either Acquired Immunodeficiency Syndrome
(AIDS) or Hepatitis B (chronic active) at the University of Naples had not been
authorized by, or commenced at, that institution.
The Registrant intends to make corrective disclosure in an amendment to its
Form 10K for the period ended December 31, 1996 as soon as its audit for the
year is completed.
SIGNATURES
----------
Pursuant to the requirements of the Securities Act of 1934, the Registrant
has duly caused this Current Report to be signed on its behalf by the
undersigned, one of its officers thereunto duly authorized.
Dated: New York, NY
June 4, 1997
MEDIZONE INTERNATIONAL, INC.
By: s/Kenneth Gropper
------------------------------------
Kenneth Gropper
